The development of HER2‐targeted therapy has been one of the greatest advances in breast cancer treatment, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs), which significantly improve the therapeutic outcome in clinic.5 Here, ERBB2 is linked to breast cancer.